The award citation highlights Tanner’s discoveries elucidating the biophysical determinants of organ-specific metastasis in a living animal. That phrasing captures a question that has long frustrated cancer researchers: why do tumor cells shed from a primary growth settle and flourish in some organs while failing in others? The prevailing view in oncology has shifted over recent decades from a purely biochemical picture, in which chemical signals and genetic mutations govern the spread of cancer, toward a more integrated framework in which physical forces, tissue architecture, and mechanical properties of the cellular microenvironment play decisive roles. Tanner’s work sits squarely at the heart of this shift, and the Biophysical Society’s decision to honor it underscores how central physics has become to modern cancer research.

Metastasis remains the deadliest phase of cancer, responsible for the majority of cancer-related deaths worldwide. For a tumor cell to seed a new colony in a distant organ, it must complete an extraordinary sequence of steps: detach from the primary tumor, invade surrounding tissue, enter the circulation or lymphatic system, survive the punishing shear stresses of blood flow, arrest in a small vessel of a distant organ, exit into the new tissue, and finally adapt to an unfamiliar microenvironment well enough to proliferate. Each of these steps imposes distinct physical demands on the cell, from squeezing through narrow gaps to withstanding fluid forces to remodeling the stiffness of the tissue around it. Understanding which of these physical hurdles determine success or failure is essential for predicting and ultimately preventing deadly spread.

Organ-specific metastasis adds another layer of complexity. Clinicians have observed for more than a century that different cancers display characteristic patterns of spread: some tumors preferentially colonize the liver, others the lung, bone, or brain. Stephen Paget’s celebrated seed and soil hypothesis, proposed in 1889, framed the problem in agricultural terms, suggesting that tumor cells, like seeds, can only grow in congenial soil. Modern research has enriched that metaphor with molecular detail, identifying chemokine signaling, extracellular matrix composition, and organ-specific stromal cells as contributors to the soil’s fertility. What has been harder to capture is the physical dimension of the soil: how the stiffness, topology, fluid dynamics, and mechanical stresses of a given organ filter and shape arriving tumor cells. Studying these factors requires tools that can probe living tissue at multiple scales simultaneously, precisely the kind of methodological territory in which biophysics excels.

Tanner’s recognition by the Biophysical Society reflects the value of approaching these questions with the quantitative rigor of a physicist. Investigating biophysical determinants in a living animal, rather than in simplified cell culture dishes, is a demanding methodological choice. Cell culture allows exquisite control and measurement, but it strips away the fluid shear of the bloodstream, the three-dimensional architecture of organs, the immune system, and the mechanical heterogeneity of real tissue. Animal models preserve that complexity but make precise physical measurement far more difficult. Bridging the two requires innovative imaging strategies, engineered model systems that recapitulate key features of organs, and analytical frameworks capable of linking single-cell behavior to tissue-level outcomes. Researchers who accomplish this bridging are rare, and the award’s emphasis on work performed in a living animal signals how highly the community values that integration.

The significance of this line of research extends well beyond fundamental understanding. If the physical properties of an organ microenvironment help determine whether disseminated tumor cells take hold, then those properties become potential therapeutic targets. Approaches that modify tissue stiffness, interfere with mechanotransduction signaling pathways by which cells sense and respond to mechanical cues, or alter the physical interactions between tumor cells and their surroundings could complement existing treatments aimed at genetic and biochemical vulnerabilities. Moreover, physical measurements of the microenvironment might one day serve as predictive biomarkers, helping clinicians assess a patient’s risk of metastasis to particular organs and tailor surveillance and intervention accordingly. Work of the kind Tanner has pursued lays the groundwork for such translational possibilities by identifying which physical variables matter most.

Bárány Award recipients are chosen for outstanding contributions to biophysics at a career stage before senior rank, making the prize a marker of exceptional early trajectory. The award honors the legacies of Michael and Kate Bárány, whose own contributions to muscle biophysics exemplified the discipline’s tradition of explaining biological function through physical principles. In recognizing Tanner, the Society continues that tradition while also highlighting the expanding scope of biophysics itself. Once concentrated on problems such as protein structure, membrane dynamics, and muscle contraction, the field now encompasses the mechanics of cancer, the physics of morphogenesis, and the quantitative analysis of intact organisms. The Society, founded in 1958, describes its mission as leading a global community working at the interface of the physical and life sciences across all levels of complexity, and its roughly 6,000 members teach and conduct research in universities, laboratories, government agencies, and industry around the world.

The announcement also offered a vivid portrait of Tanner as a scientist. BPS President Karen Fleming of Johns Hopkins University described her as an innovative thinker and a fearless experimentalist, adding that Tanner has established herself as a world leader in the research community that investigates the impact of physical properties on complex biological processes within tissue and within intact organisms. The characterization is notable for its emphasis on fearlessness. Experiments that probe physical forces inside living animals demand technical ingenuity and a tolerance for systems that resist the tidy controls of the physics laboratory. The praise from the Society’s president suggests that Tanner’s willingness to tackle biology at its most complicated and least controllable has been central to her standing in the field.

The February 2027 meeting in Philadelphia will bring together thousands of biophysicists for a program spanning molecular, cellular, and organismal scales, and the award lecture that accompanies the Bárány honor will give Tanner a prominent platform to describe her findings to that audience. For the broader cancer research community, the recognition serves as a reminder that the physical sciences are no longer peripheral to oncology. The spread of cancer through the body is, at its core, a problem of cells navigating a physical world: deforming through confined spaces, sensing the rigidity of the ground beneath them, enduring the rush of blood, and remodeling the architecture of the tissues they invade. By illuminating the biophysical determinants of organ-specific metastasis in living animals, Tanner’s work addresses one of the most consequential questions in medicine with the tools of physics, and the 2027 Michael and Kate Bárány Award marks both her achievements and the growing conviction that understanding cancer requires understanding its physics.

Subject of Research: Biophysical mechanisms of organ-specific cancer metastasis recognized by the 2027 Michael and Kate Bárány Award

Article Title: Kandice Tanner to receive 2027 Michael and Kate Bárány Award

Article References: Kandice Tanner to receive 2027 Michael and Kate Bárány Award. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Kandice Tanner, Biophysical Society, Bárány Award, metastasis, biophysics, National Cancer Institute, organ-specific metastasis, tumor microenvironment, mechanobiology, cancer research, living animal models, scientific award

KRAS is one of the most frequently mutated oncogenes in human cancer, and in this cohort it was altered in 45.7 percent of the colorectal tumors sequenced. The gene encodes a small GTP-binding protein that sits at the top of growth-factor signaling pathways, cycling between an active, GTP-bound state and an inactive, GDP-bound state. Mutations at codon 12 and related hotspots impair the protein’s GTPase activity, locking KRAS into its active conformation and driving constitutive signaling through the MAPK and PI3K pathways. But not all codon-12 substitutions are biochemically identical. G12C, G12V, and G12A alter different amino acids and produce different kinetics of nucleotide binding and downstream signaling, and the new study shows that these biochemical differences translate into clinically meaningful divergence.

The retrospective study, led by a team at Zhongshan Hospital, Fudan University, integrated targeted next-generation sequencing with detailed clinical outcome data. When the researchers stratified patients by specific KRAS allele, a striking prognostic hierarchy emerged. Among patients with stage I-III disease, those whose tumors carried G12C or G12V mutations had dramatically poorer disease-free survival than patients with KRAS wildtype tumors, with hazard ratios of 9.3 and 4.6, respectively, and p values below 0.001. In the metastatic setting, a different allele took the lead: G12A was associated with the worst progression-free survival among stage IV patients, carrying a hazard ratio of 9.6. In other words, the most dangerous KRAS subtype depends on the stage of disease being considered, a nuance that conventional binary KRAS testing entirely obscures.

The study also uncovered a connection between KRAS alleles and the organs to which tumors preferentially spread, a phenomenon known as metastatic organotropism. Tumors harboring G12V and G12C mutations showed pronounced tropism for the liver, while G12A-mutant tumors were enriched in bone metastases. This allelic mapping of metastatic behavior has practical implications. Clinicians already know that the site and burden of metastatic disease shape treatment decisions and prognosis; if the KRAS allele helps predict where a tumor will seed, subtype-level genotyping could add a layer of anticipatory surveillance that is currently absent from standard practice.

To understand the biology underlying these clinical patterns, the investigators turned to the tumor microenvironment, analyzing bulk and single-cell RNA sequencing data. Bulk transcriptomic analysis revealed that tumors carrying the aggressive G12A, G12C, and G12V variants were characterized by significantly lower immune cell infiltration and by suppression of interferon response pathways. Interferon signaling is a central arm of innate anti-tumor immunity, and its dampening suggests that these KRAS variants do not merely grow faster; they actively sculpt a microenvironment in which immune cells are fewer, less alert, and less capable of recognizing malignant tissue. An immune-excluded phenotype of this kind is also a known predictor of poor response to immunotherapy, providing a mechanistic bridge between the observed survival deficits and the immunological landscape of the tumors.

Single-cell RNA sequencing sharpened the picture further. The immunosuppressive phenotype appeared to be linked to stromal remodeling, specifically involving cancer-associated fibroblasts, the stromal cells that infiltrate tumors and profoundly influence their behavior. In the aggressive KRAS subtypes, the researchers found enrichment of pro-tumorigenic CXCL14-expressing cancer-associated fibroblasts and depletion of protective IGF1-expressing fibroblasts, with CD74-positive fibroblasts similarly reduced. CXCL14-positive CAFs are thought to promote tumor progression through chemokine-mediated recruitment and immunomodulatory effects, whereas IGF1-positive populations have been associated with protective, less permissive stromal contexts. Analysis of intercellular communication networks reinforced the finding, showing that KRAS mutation status reshapes the signaling conversations between tumor cells, fibroblasts, and immune cells.

The clinical consequences of this work could be substantial. Today, KRAS testing in colorectal cancer is largely binary, performed chiefly to determine eligibility for anti-EGFR antibodies such as cetuximab and panitumumab, which are ineffective in KRAS-mutant tumors. The new data argue that reporting should extend to the specific allele. A patient with a stage II tumor carrying G12C may warrant more intensive surveillance than the stage alone would suggest, while a metastatic patient with G12A may face a particularly poor trajectory that could justify earlier escalation of systemic therapy. The authors propose that their allele-specific landscape provides a rationale for refining prognostic models and for tailoring therapeutic strategies to the vulnerabilities of each KRAS subtype.

Therapeutically, the timing is propitious. For decades KRAS was considered undruggable, but the 2021 approval of KRAS G12C inhibitors transformed the field, and allele-specific agents for other variants are in development. The demonstration that G12C tumors carry a distinctly immunosuppressive, interferon-suppressed microenvironment raises testable questions about combination strategies, particularly pairing allele-specific inhibitors with immunotherapy or with agents that remodel stromal signaling. Similarly, the identification of CXCL14-positive fibroblasts as a feature of aggressive subtypes points to stromal targets that could be exploited regardless of direct KRAS druggability.

The study has the usual limitations of retrospective work. It drew on a single institutional cohort, and the authors note that findings will require validation in independent datasets and prospective studies before prognostic models can be revised. The survival analyses were adjusted for available clinicopathological variables, but unrecognized confounders can never be fully excluded in this design. The single-cell component, while providing mechanistic depth, involved a smaller subset of patients. Nevertheless, the consistency between the clinical, bulk transcriptomic, and single-cell layers of evidence lends weight to the central conclusion that KRAS subtypes are biologically non-equivalent.

What makes the study resonate beyond colorectal cancer is its conceptual message. Oncology has been moving toward allele-level precision for years in lung cancer, where EGFR and ALK genotypes dictate therapy, but KRAS in colorectal cancer has remained a blunt category. By showing that hazard ratios of the same order as major staging variables attach to specific KRAS alleles, the researchers effectively argue that a G12V tumor and a G12A tumor are different diseases that happen to share a gene. If validated, subtype-level KRAS annotation could become a routine element of colorectal cancer pathology reports, joining microsatellite instability and RAS/BRAF status as a standard axis of risk stratification.

For patients, the immediate message is not a new drug but a sharper question to ask: not simply whether a tumor is KRAS-mutant, but which KRAS mutation it carries. For oncologists, the study offers a data-driven basis for reinterpreting a mutation they already measure, and for researchers, it maps a set of concrete vulnerabilities, from interferon suppression to CXCL14-positive stromal niches, that define the biology of the most aggressive KRAS alleles. As the authors conclude, deconstructing the monolithic view of KRAS-mutant colorectal cancer may be the first step toward therapies designed not around a gene, but around the specific molecular entity each mutation creates.